Pieris Pharmaceuticals GmbH is a wholly owned subsidiary of Pieris Pharmaceuticals Inc. in Boston and concluded a lease agreement for a property in Halbergmoos near Munich Airport in October 2018. The new facility, with an area of around 9,000 square meters, will allow Pieris to further expand its research and development activities and boost the German-based team. Pieris assumes that the move from the current location, the Innovation- and Start-up Center for Biotechnology (IZB) in Freising-Weihenstephan, to the new location will take place towards the end of 2019.
“We are delighted to have signed this new lease agreement, which will provide Pieris with the basis for further growth as a company and innovator in Germany,” said Stephen Yoder, President and CEO of Pieris. “We are grateful to the IZB for providing us with our first base in Germany. We are now at an optimal time to move to a larger and specially designed building that meets our needs as a research and development organization.
Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. The pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, inhalable Anticalin proteins to treat respiratory diseases and a half-life-optimized Anticalin protein to treat anemia.